Our current product development programs are focused on product candidates in the fields of psychiatry and neurology. Our portfolio consists of the following two product candidates:
Product
Indication
Patent Rights
Marketing Rights
Phase of Development
SILENOR™ (doxepin HCl tablets)
Insomnia
United States
Worldwide
NDA accepted for filing as of 3/31/08. PDUFA action date 12/1/08.
Nalmefene HCl
Pathological gambling and other impulse control disorders
